Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians ; volume:102 ; number:12 ; day:15 ; month:9 ; year:2023 ; pages:3639-3641 ; date:12.2023
Annals of hematology ; 102, Heft 12 (15.9.2023), 3639-3641, 12.2023
- Creator
-
Dieterle, Martin P.
Mostufi-Zadeh-Haghighi, Gila
Kus, Jan Wilhelm
Wippel, Christopher
Brugger, Zacharias
Miething, Cornelius
Wäsch, Ralph
Engelhardt, Monika
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-023-05451-8
- URN
-
urn:nbn:de:101:1-2024013013021969103966
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dieterle, Martin P.
- Mostufi-Zadeh-Haghighi, Gila
- Kus, Jan Wilhelm
- Wippel, Christopher
- Brugger, Zacharias
- Miething, Cornelius
- Wäsch, Ralph
- Engelhardt, Monika
- SpringerLink (Online service)
Other Objects (12)
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Allogeneic stem cell transplantation in multiple myeloma
The role of the APC/C and its coactivators Cdh1 and Cdc20 in cancer development and therapy
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Response to daratumumab-retreatment in patients with multiple myeloma
Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians
Geriatric assessments and frailty scores in multiple myeloma patients : : a needed tool for individualized treatment?
Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long‐term follow‐up of 815 patients
In search of the optimal proteosome inhibitor. How, when and for whom?
Das interdisziplinäre Tumorboard „Multiples Myelom“ des Comprehensive Cancer Center Freiburg: eine Reanalyse
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Allogeneic stem cell transplantation in multiple myeloma
The role of the APC/C and its coactivators Cdh1 and Cdc20 in cancer development and therapy
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Response to daratumumab-retreatment in patients with multiple myeloma
Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians
Geriatric assessments and frailty scores in multiple myeloma patients : : a needed tool for individualized treatment?
Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long‐term follow‐up of 815 patients
In search of the optimal proteosome inhibitor. How, when and for whom?
Das interdisziplinäre Tumorboard „Multiples Myelom“ des Comprehensive Cancer Center Freiburg: eine Reanalyse
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Allogeneic stem cell transplantation in multiple myeloma
The role of the APC/C and its coactivators Cdh1 and Cdc20 in cancer development and therapy
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Response to daratumumab-retreatment in patients with multiple myeloma
Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians
Geriatric assessments and frailty scores in multiple myeloma patients : : a needed tool for individualized treatment?
Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long‐term follow‐up of 815 patients
In search of the optimal proteosome inhibitor. How, when and for whom?